OBJECTIVE: Many premature infants at risk for bronchopulmonary dysplasia experience episodes of surfactant dysfunction with reduced surfactant protein B (SP-B). In this study, we investigated the safety and responses to booster doses of surfactant. STUDY DESIGN: A total of 87 infants, 500 to 1250 g birth weight, who were ventilated at 7 to 10 days received 2 or 3 doses of Infasurf (Calfactant, Forest Pharmaceuticals, St Louis, MO, USA) within a 1-week period. RESULT: For 184 doses, occurrence rates of transient bradycardia (13) and plugged endotracheal tube (5) were low, and no other adverse effects were noted. Treatment transiently improved the respiratory severity score (FiO(2) × mean airway pressure), SP-B content (+75%) and surface properties of isolated surfactant. Levels of eight proinflammatory cytokines in tracheal aspirate were interrelated and unchanged from baseline after surfactant treatment. CONCLUSION: Booster doses of surfactant for premature infants with lung disease are safe and transiently improve respiratory status as well as composition and function of endogenous surfactant.
OBJECTIVE: Many premature infants at risk for bronchopulmonary dysplasia experience episodes of surfactant dysfunction with reduced surfactant protein B (SP-B). In this study, we investigated the safety and responses to booster doses of surfactant. STUDY DESIGN: A total of 87 infants, 500 to 1250 g birth weight, who were ventilated at 7 to 10 days received 2 or 3 doses of Infasurf (Calfactant, Forest Pharmaceuticals, St Louis, MO, USA) within a 1-week period. RESULT: For 184 doses, occurrence rates of transient bradycardia (13) and plugged endotracheal tube (5) were low, and no other adverse effects were noted. Treatment transiently improved the respiratory severity score (FiO(2) × mean airway pressure), SP-B content (+75%) and surface properties of isolated surfactant. Levels of eight proinflammatory cytokines in tracheal aspirate were interrelated and unchanged from baseline after surfactant treatment. CONCLUSION: Booster doses of surfactant for premature infants with lung disease are safe and transiently improve respiratory status as well as composition and function of endogenous surfactant.
Authors: Philip L Ballard; Dara Torgerson; Rajan Wadhawan; Mark L Hudak; Joern-Hendrik Weitkamp; Julia Harris; Jeanette Asselin; Cheryl Chapin; Roberta A Ballard; Cindy T McEvoy Journal: Pediatr Res Date: 2021-01-19 Impact factor: 3.756
Authors: Roberta L Keller; Jeffrey D Merrill; Dennis M Black; Robin H Steinhorn; Eric C Eichenwald; David J Durand; Rita M Ryan; William E Truog; Sherry E Courtney; Philip L Ballard; Roberta A Ballard Journal: Pediatr Res Date: 2012-10-04 Impact factor: 3.756
Authors: Shashi P Singh; Sravanthi Gundavarapu; Kevin R Smith; Hitendra S Chand; Ali Imran Saeed; Neerad C Mishra; Julie Hutt; Edward G Barrett; Matloob Husain; Kevin S Harrod; Raymond J Langley; Mohan L Sopori Journal: Environ Health Perspect Date: 2013-06-11 Impact factor: 9.031